Introduction
============

Previous studies have reported the relationship between gastroesophageal reflux disease (GERD) and respiratory disease, including asthma, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis (IPF).[@b1-jnm-22-444]--[@b3-jnm-22-444] In particular, many studies have reported the higher prevalence of GERD in IPF.[@b4-jnm-22-444]--[@b13-jnm-22-444] The prevalence of GERD in patients with IPF was reportedly 67 to 88% in Western populations,[@b8-jnm-22-444]--[@b10-jnm-22-444],[@b12-jnm-22-444],[@b13-jnm-22-444] and 62.3% (43 of 69 patients) in China.[@b6-jnm-22-444] Although the mechanism is unclear, chronic microaspiration due to GERD has been considered to be one of the causes of IPF through repeated subclinical injury to the lungs.[@b7-jnm-22-444],[@b8-jnm-22-444],[@b12-jnm-22-444],[@b14-jnm-22-444]--[@b17-jnm-22-444] This is supported by the lower pH or elevated concentrations of pepsin in bronchoalveolar lavage in patients with IPF.[@b18-jnm-22-444],[@b19-jnm-22-444] Esophageal manometry in patients with GERD and IPF shows decreased lower esophageal sphincter pressure (LESP) with normal esophageal function, and further decreased upper esophageal sphincter pressure than LESP.[@b6-jnm-22-444],[@b20-jnm-22-444] These findings may explain why typical symptoms such as heartburn are uncommon in patients with IPF.[@b6-jnm-22-444],[@b14-jnm-22-444],[@b16-jnm-22-444],[@b20-jnm-22-444]

Moreover, Lee et al[@b21-jnm-22-444] reported that GERD influences the survival rate in patients with IPF, as well as the development of IPF. This study also reported that symptoms of GERD, a history of GERD, medication for GERD, and Nissen fundoplication were independent predictors of longer survival for IPF. Another study reported that antacid therapy including antihistamines, sucralfate, and proton pump inhibitors (PPI) reduced the frequency of acute exacerbations and slowed the deterioration of forced vital capacity (FVC).[@b22-jnm-22-444] Another case series showed that anti-reflux therapy with PPI alone stabilized or improved pulmonary function tests in IPF.[@b23-jnm-22-444]

Standard treatment for atypical GERD has been proposed as PPI twice daily for 3--4 months.[@b3-jnm-22-444],[@b24-jnm-22-444] In cases of laryngopharyngeal reflux, some experts recommend treatment with PPI for at least 4--6 months in order to improve the symptoms.[@b25-jnm-22-444],[@b26-jnm-22-444] However, in respiratory manifestations of GERD, the appropriate duration and effectiveness of PPI medication are still controversial.

The aims of this study were to investigate the prevalence of GERD in Korean patients with IPF, and to compare the differences in survival according to the duration of PPI treatment.

Materials and Methods
=====================

Study Populations
-----------------

This is a retrospective, single-center cohort study involving a total of 917 consecutive adult patients with IPF seen at Seoul National University Bundang Hospital between April 2003 and March 2015. Of these, patients with underlying asthma or COPD were excluded; therefore, a total of 786 patients were enrolled. All patients were given diagnoses of IPF by respiratory specialists. IPF is defined as a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause, occurring primarily and in association with histologic and/or radiologic patterns of usual interstitial pneumonia.[@b27-jnm-22-444] Demographic data including age, sex, body mass index (BMI), concomitant diseases, alcohol consumption, smoking, medication history, pulmonary function, and computed tomography data were retrospectively collected from a review of medical records. GERD was diagnosed according to typical symptoms including typical heartburn and acid regurgitation. Erosive reflux disease (ERD) was defined by mucosal breaks on endoscopy, and nonerosive reflux disease (NERD) was diagnosed after reflux monitoring and/or PPI response in addition to negative endoscopy. This study was conducted in accordance with the amended Declaration of Helsinki. The Institutional Review Board of Seoul National University Bundang Hospital reviewed and approved the protocol (B-1507-306-126).

Outcome
-------

The primary outcomes were the prevalence of GERD and cumulative incidence of de novo GERD in patients with IPF at Seoul National University Bundang Hospital in Korea. The secondary outcomes were IPF-related mortality and the predictive risk factors for IPF-related mortality according to variables, including duration of medication with PPI in patients with IPF.

Statistical Methods
-------------------

For between-group comparisons, the Chi-square test or Fisher's exact test (for situations with small frequencies) was used for categorical variables, and Student's *t* test was used for continuous variables. The cumulative incidence of de novo GERD and IPF-related mortality curves were constructed using Kaplan-Meier analysis, and compared using the log-rank test. The association between variables and IPF-related mortality was assessed by univariate and multivariate Cox proportional hazard regression analysis. The risk was expressed by calculating the hazard ratio (HR) and 95% confidence interval (CI). A *P*-value \< 0.05 was considered to indicate a statistically significant difference. All statistical analyses were performed using SPSS 22.0 (SPSS, Chicago, IL, USA).

Results
=======

Baseline Characteristics
------------------------

Mean age ± standard deviation was 75.2 ± 10.3 years, and 559 (71.1%) were men ([Table 1](#t1-jnm-22-444){ref-type="table"}). Mean BMI was 22.6 ± 3.9 kg/m^2^. Mean duration of follow-up was 2.6 ± 2.8 years. A total 294 (37.4%) were given prednisolone. Of the 128 who were given azathioprine, 118 (92.2%) were coadministered prednisolone; aza-thioprine alone was given to 10 patients. Inhaled corticosteroids/long-acting beta2-agonists (ICS/LABA) were used in 42 (5.3%). We performed esophagogastroduodenoscopy (EGD) in 25.2% of cases, while esophageal manometry and 24-hour pH monitoring were done in only 2 patients.

There was no significant difference in mean age, BMI, and sex between patients with and without GERD. However, the proportion undergoing EGD was significantly higher for those with GERD than in those without GERD (78.5% vs 16.8%, *P* \< 0.001) ([Table 1](#t1-jnm-22-444){ref-type="table"}). Initial FVC was significantly higher and duration of follow-up was also significantly longer in patients with GERD. In addition, hypertension (HTN), diabetes mellitus, and angina were more likely in patients with GERD.

The Prevalence of Gastroesophageal Reflux Disease and the Cumulative Incidence of De Novo Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis
----------------------------------------------------------------------------------------------------------------------------------------------------------

Of the 786 patients with IPF, GERD was diagnosed in 107 (13.6%). Of these 107, 84 (78.5%) underwent EGD for diagnosis of GERD, and 23 (21.5%) with typical symptoms were given diagnoses without EGD ([Table 1](#t1-jnm-22-444){ref-type="table"}). Of 84 patients who underwent EGD, the proportion with ERD was 18 (21.4%), and 66 (78.6%) had NERD ([Fig. 1A](#f1-jnm-22-444){ref-type="fig"}). Of 679 IPF patients without GERD, 161 (23.7%) used PPI for treatment of peptic ulcer or diagnosis of GERD.

On the other hand, 57/107 (53.3%) were newly diagnosed with GERD following the diagnosis of IPF (de novo GERD) ([Fig. 1B](#f1-jnm-22-444){ref-type="fig"}). However, the other cases of GERD (50/107, 46.7%) were diagnosed before IPF was diagnosed.

The prevalence of GERD tended to increase as the follow-up period increased ([Fig. 2A](#f2-jnm-22-444){ref-type="fig"}). In 736 patients without underlying GERD, the cumulative incidence of de novo GERD increased consistently after the diagnosis of IPF ([Fig. 2B](#f2-jnm-22-444){ref-type="fig"}).

Predictive Risk Factors for Idiopathic Pulmonary Fibrosis-related Mortality
---------------------------------------------------------------------------

Of 786 patients with IPF, 156 (19.8%) died regardless of the cause, and 103 (13.1%) died due to IPF-related pneumonia or respiratory failure. In Kaplan-Meier analysis, IPF-related mortality was significantly lower in those who took PPI for more than four months than in those who took PPI for less than four months (log rank, *P* = 0.024). However, when the cut-off value was set at 2 or 3 months, there was no significant difference in IPF-related mortality ([Fig. 3](#f3-jnm-22-444){ref-type="fig"}).

In the univariate Cox regression hazard model, IPF-related mortality was significantly associated with age, BMI, initial FVC, prednisolone, azathioprine, ICS/LABA, PPI for four months, duration of PPI use, underlying HTN, and pulmonary HTN ([Table 2](#t2-jnm-22-444){ref-type="table"}). In the multivariate Cox model 1, IPF-related mortality was significantly associated with age, initial FVC, azathioprine, pulmonary HTN, and duration of PPI use. However, in the multivariate Cox model 2, IPF-related mortality was associated with only age, initial FVC, and HTN, but not GERD or PPI dosing. In both multivariate Cox models, the hazard risk for IPF-related mortality increased with increasing age and decreasing initial FVC. However, there was no significant association between IPF-related mortality and GERD in either model. Although there was an inverse association between IPF-related mortality and duration of PPI dosing in model 1, PPI taken for 4 months was not a significant independent predictive factor for IPF-related mortality in model 2.

Discussion
==========

In the present study, the prevalence of GERD was 13.6% (107/786) in patients with IPF in Korea. This result is much lower than the prevalence reported in other countries, including China.[@b6-jnm-22-444],[@b8-jnm-22-444]--[@b10-jnm-22-444],[@b12-jnm-22-444],[@b13-jnm-22-444] In addition, this result is lower than the prevalence of asthma or COPD previously reported in the Korean population (55.6% and 30%, respectively).[@b28-jnm-22-444],[@b29-jnm-22-444] While this low prevalence of GERD in IPF is probably due to ethnic characteristics in the Korean population, there is a possibility that GERD was diagnosed by gastroenterologists based on strict criteria. Furthermore, this may explain why typical GERD symptoms such as heartburn or reflux were uncommon in patients with respiratory manifestations of GERD.[@b6-jnm-22-444],[@b14-jnm-22-444],[@b16-jnm-22-444],[@b20-jnm-22-444] Another possibility is that the prevalence of GERD may have been underestimated in the present study, because 31.8% (248/786) were lost to follow-up within six months. Among patients who continued follow-up for over six months, the prevalence of GERD in IPF was slightly increased to 17.3% (93/538). Furthermore, a longer duration of follow-up tended to increase the prevalence of GERD (up to 65.3% on the Kaplan-Meier curve) ([Fig. 1A](#f1-jnm-22-444){ref-type="fig"}).

We investigated the time to onset of GERD, and found that of 107 patients with GERD and IPF, 50 (46.7%) had been diagnosed with GERD before a diagnosis of IPF, and 57 (53.3%) were newly diagnosed after a diagnosis of IPF. This suggests that GERD could occur at any time, regardless of the diagnosis of IPF. In 736 patients without underlying GERD at the time of diagnosis of IPF, the cumulative incidence of de novo GERD showed a tendency to continuous increase ([Fig. 2B](#f2-jnm-22-444){ref-type="fig"}). However, there was no predictive factor for the development of de novo GERD in patients with IPF.

IPF-related causes of death, including pneumonia or respiratory failure, totaled 13.1% (103/786), and death due to any cause totaled 19.8% (156/786). In the present study, older age and lower initial FVC increased IPF-related mortality significantly in multivariate Cox regression analysis ([Table 2](#t2-jnm-22-444){ref-type="table"}). Although a history of azathioprine use was also associated with more frequent IPF-related deaths, this association may be due to confounding factors based on the severity of IPF. In a retrospective cohort study in the USA, Lee et al[@b21-jnm-22-444] reported that the presence of reflux symptoms, GERD, GERD medication, and Nissen fundoplication were significantly associated with longer survival time. Similar to these results, GERD was also significantly associated with lower IPF-related death in univariate Cox analysis in the present study. However, in multivariate Cox regression analysis, GERD itself was not an independent predictive factor for IPF-related mortality ([Table 2](#t2-jnm-22-444){ref-type="table"}). On the contrary, PPI use was correlated with IPF mortality in the present study.

Compared to previous studies, PPI use for longer periods was associated with a reduced IPF-related mortality rate. Although PPI use for two or three months was not significantly correlated, PPI use for over four months showed a lower IPF-related mortality rate than use for less than four months ([Fig. 2](#f2-jnm-22-444){ref-type="fig"}). In addition, longer duration of PPI use was a significant independent predictive factor for low IPF-related mortality rates in univariate and multivariate Cox regression analysis ([Table 2](#t2-jnm-22-444){ref-type="table"}). These results suggest that PPI use is associated with good prognosis in IPF, and that use of PPI for at least four months may have a protective effect against IPF-related death. However, longer PPI use had a higher correlation with IPF-related mortality than did GERD. Because patients with GERD had a higher proportion of PPI use than patients without GERD (*P* \< 0.001), the association between GERD and survival in univariate analysis was probably due to an association between GERD and PPI use. Patients with GERD had another basis for good prognosis. We surmised that IPF-related mortality may be influenced by better FVC at baseline in patients with GERD than in those without GERD ([Table 1](#t1-jnm-22-444){ref-type="table"}).

The main limitation of the present study was that it was a single-center retrospective study. In addition, the lower prevalence and mortality rates compared to those in previous studies may have been due to the higher proportion of loss to follow-up within 6 months. Insufficient evaluation of patients without GERD symptoms may also have contributed to underestimation. Furthermore, it should be noted that it was difficult to analyze atypical symptoms of GERD due to uncertainty of relationship between GERD and these symptoms. Therefore, further prospective studies are needed to verify the effectiveness of PPI in improving the prognosis of IPF. Another limitation is that PPI is also related with community-acquired pneumonia (CAP), and CAP is associated with IPF-related mortality. Although CAP might be a confounding factor, this is a rare data that improve a statistically significant relationship between PPI and IPF-related mortality. Moreover, there are no data available regarding patients with IPF and GERD in Korea.

In conclusion, in Korean patients with IPF, the prevalence of GERD was relatively low, compared to other countries. PPI treatment was more important to survival than GERD itself in patients with IPF. The IPF-related mortality rate was significantly associated with the use of PPI medication for longer than four months in patients with IPF.
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###### 

Baseline Characteristics of Patients with Idiopathic Pulmonary Fibrosis

  Variable                     Total patients (N = 786)   Patients with GERD (n = 107)   Patients without GERD (n = 679)   *P*-value
  ---------------------------- -------------------------- ------------------------------ --------------------------------- ----------------------------------------------------
  Age (yr)                     75.2 ± 10.3                75.2 ± 9.9                     75.1 ± 10.3                       0.945
  Sex (male)                   559 (71.1)                 78 (72.9)                      481 (70.8)                        0.662
  BMI (kg/m^2^)                22.6 ± 3.9                 22.5 ± 3.8                     22.6 ± 4.0                        0.849
  Duration of follow-up (yr)   2.6 ± 2.8                  3.9 ± 2.9                      2.3 ± 2.8                         \< 0.001[a](#tfn1-jnm-22-444){ref-type="table-fn"}
  Initial FVC (% predicted)    84.0 ± 20.5                89.3 ± 19.8                    83.0 ± 20.5                       0.006[a](#tfn1-jnm-22-444){ref-type="table-fn"}
  Duration of PPI (wk)         24.5 ± 54.5                47.9 ± 88.9                    15.1 ± 26.8                       0.001[a](#tfn1-jnm-22-444){ref-type="table-fn"}
  Alcohol consumption          195 (37.2)                 29 (36.3)                      166 (37.4)                        0.846
  Smoking history              269 (65.9)                 43 (62.3)                      226 (66.7)                        0.487
  Medication history                                                                                                       
   Acetylcysteine              385 (49.0)                 67 (62.6)                      318 (46.8)                        0.002[a](#tfn1-jnm-22-444){ref-type="table-fn"}
   Prednisolone                294 (37.4)                 40 (37.4)                      254 (37.4)                        0.996
   Azathioprine                128 (16.3)                 16 (15.0)                      112 (16.5)                        0.688
   Tiotropium                  46 (5.9)                   8 (7.5)                        38 (5.6)                          0.441
   ICS/LABA                    42 (5.3)                   5 (4.7)                        37 (5.4)                          0.740
   Warfarin                    26 (3.3)                   4 (3.7)                        22 (3.2)                          0.771
   Sildenafil                  19 (2.4)                   7 (6.5)                        12 (1.8)                          0.009[a](#tfn1-jnm-22-444){ref-type="table-fn"}
  EGD                          198 (25.2)                 84 (78.5)                      114 (16.8)                        \< 0.001[a](#tfn1-jnm-22-444){ref-type="table-fn"}
   Peptic ulcer disease        55/198 (27.8)              26/84 (31.0)                   29/114 (25.4)                     0.392
  Comorbidity                                                                                                              
   HTN                         143 (18.2)                 32 (29.9)                      111 (16.3)                        0.001[a](#tfn1-jnm-22-444){ref-type="table-fn"}
   DM                          125 (15.9)                 22 (20.6)                      103 (15.2)                        0.156
   Angina                      74 (9.4)                   18 (16.8)                      56 (8.2)                          0.005[a](#tfn1-jnm-22-444){ref-type="table-fn"}
   CKD                         11 (1.4)                   0 (0.0)                        11 (1.6)                          0.377
   LC                          6 (0.8)                    0 (0.0)                        6 (0.9)                           1.000
   Pulmonary HTN               6 (0.8)                    1 (0.9)                        5 (0.7)                           0.586

*P*-value was below 0.05.

GERD, gastroesophageal reflux disease; BMI, body mass index; FVC, forced vital capacity; PPI, proton pump inhibitor; ICS/LABA, inhaled corticosteroids/long-acting beta2-agonists; EGD, esophagogastroduodenoscopy; HTN, hypertension; DM, diabetes mellitus; CKD, chronic kidney disease; LC, liver cirrhosis.

Data are presented as mean ± SD or number (%).

###### 

Cox Regression Analysis of the Predictive Risk Factors for Idiopathic Pulmonary Fibrosis-related Mortality

  Variable                                                     Univariate analysis   Multivariate analysis (Model 1)                      Multivariate analysis (Model 2)                                                                          
  ------------------------------------------------------------ --------------------- ---------------------------------------------------- --------------------------------- ------------------------------------------------- -------------------- ----------------------------------------------------
  Age (yr)                                                     1.03 (1.01--1.05)     0.005[b](#tfn5-jnm-22-444){ref-type="table-fn"}      1.06 (1.03--1.10)                 0.001[b](#tfn5-jnm-22-444){ref-type="table-fn"}   1.05 (1.02--1.09)    \< 0.001[b](#tfn5-jnm-22-444){ref-type="table-fn"}
  BMI (kg/m^2^)                                                0.92 (0.88--0.97)     0.003[b](#tfn5-jnm-22-444){ref-type="table-fn"}      1.01 (0.92--1.11)                 0.872                                             0.99 (0.92--1.06)    0.729
  Sex (male)                                                   0.78 (0.49--1.22)     0.270                                                                                                                                                         
  Alcohol consumption                                          1.24 (0.83--1.85)     0.305                                                                                                                                                         
  Smoking history                                              0.84 (0.65--1.70)     0.842                                                                                                                                                         
  Initial FVC (% predicted)                                    0.98 (0.97--0.98)     \< 0.001[b](#tfn5-jnm-22-444){ref-type="table-fn"}   0.98 (0.96--0.99)                 0.004[b](#tfn5-jnm-22-444){ref-type="table-fn"}   0.98 (0.97--0.99)    \< 0.001[b](#tfn5-jnm-22-444){ref-type="table-fn"}
  Prednisolone                                                 2.09 (1.41--3.11)     \< 0.001[b](#tfn5-jnm-22-444){ref-type="table-fn"}   1.01 (0.48--2.42)                 0.852                                             1.23 (0.63--2.40)    0.544
  Azathioprine                                                 3.01 (2.03--4.46)     \< 0.001[b](#tfn5-jnm-22-444){ref-type="table-fn"}   2.79 (1.31--5.94)                 0.008[b](#tfn5-jnm-22-444){ref-type="table-fn"}   1.85 (0.99--3.46)    0.056
  ICS/LABA                                                     2.13 (1.13--3.99)     0.019[b](#tfn5-jnm-22-444){ref-type="table-fn"}      1.00 (0.38--2.67)                 0.997                                             1.32 (0.58--3.02)    0.507
  Tiotropium                                                   1.13 (0.55--2.32)     0.746                                                                                                                                                         
  Acetylcysteine                                               0.87 (0.59--1.29)     0.495                                                                                                                                                         
  Sildenafil                                                   0.90 (0.29--2.83)     0.857                                                                                                                                                         
  Warfarin                                                     0.44 (0.11--1.77)     0.246                                                                                                                                                         
  PPI for 2 months[a](#tfn4-jnm-22-444){ref-type="table-fn"}   0.87 (0.54--1.41)     0.572                                                                                                                                                         
  PPI for 4 months[a](#tfn4-jnm-22-444){ref-type="table-fn"}   0.47 (0.23--0.92)     0.028[b](#tfn5-jnm-22-444){ref-type="table-fn"}                                                                                          0.51 (0.21--1.22)    0.130
  Duration of PPI (wk)                                         0.97 (0.96--0.99)     0.001[b](#tfn5-jnm-22-444){ref-type="table-fn"}      0.97 (0.95--1.00)                 0.022[b](#tfn5-jnm-22-444){ref-type="table-fn"}                        
  GERD                                                         0.40 (0.20--0.80)     0.009[b](#tfn5-jnm-22-444){ref-type="table-fn"}      0.62 (0.26--1.46)                 0.274                                             0.72 (0.33--1.58)    0.413
  NERD                                                         0.35 (0.14--0.85)     0.021[b](#tfn5-jnm-22-444){ref-type="table-fn"}                                                                                                               
  ERD                                                          0.05 (0.00--6.73)     0.228                                                                                                                                                         
  Peptic ulcer                                                 1.09 (0.43--2.73)     0.857                                                                                                                                                         
  Pulmonary HTN                                                4.30 (1.06--17.51)    0.042[b](#tfn5-jnm-22-444){ref-type="table-fn"}      37.89 (4.10--349.89)              0.001[b](#tfn5-jnm-22-444){ref-type="table-fn"}   5.45 (0.71--41.97)   0.104
  HTN                                                          0.52 (0.30--0.90)     0.020[b](#tfn5-jnm-22-444){ref-type="table-fn"}      0.55 (0.25--1.20)                 0.134                                             0.50 (0.26--0.99)    0.046[b](#tfn5-jnm-22-444){ref-type="table-fn"}
  DM                                                           1.11 (0.69--1.78)     0.663                                                                                                                                                         
  Angina                                                       0.60 (0.28--1.30)     0.194                                                                                                                                                         
  CKD                                                          0.05 (0.00--17.88)    0.313                                                                                                                                                         

Categorical variables were used in the analysis.

*P*-value was below 0.05.

HR, hazard ratio; BMI, body mass index; FVC, forced vital capacity; ICS/LABA, inhaled corticosteroids/long-acting beta2-agonists; PPI, proton pump inhibitor; GERD, gastroesophageal reflux disease; NERD, non-erosive reflux disease; ERD, erosive reflux disease; HTN, hypertension; DM, diabetes mellitus; CKD, chronic kidney disease.
